文献

J-GLOBAL ID：201802256179004893   整理番号：18A0750969

IL-21は好中球浸潤の調節を介して心筋虚血/再潅流障害を促進する【JST・京大機械翻訳】

IL-21 promotes myocardial ischaemia/reperfusion injury through the modulation of neutrophil infiltration

著者 (30件)： Wang Kejing (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Wang Kejing (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Wen Shuang (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Wen Shuang (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Jiao Jiao (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Jiao Jiao (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Tang Tingting (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Tang Tingting (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Zhao Xin (Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China) ,  Zhang Min (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Zhang Min (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Lv Bingjie (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Lv Bingjie (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Lu Yuzhi (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Lu Yuzhi (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Zhou Xingdi (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Zhou Xingdi (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Li Jingyong (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Li Jingyong (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Nie Shaofang (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Nie Shaofang (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Liao Yuhua (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Liao Yuhua (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Wang Qing (Key Laboratory of Molecular Biophysics of the Ministry of Education, Cardio-X Institute, College of Life Science and Technology and Center of Human Genome Research, Huazhong University of Science and Technology, Wuhan, China) ,  Tu Xin (Key Laboratory of Molecular Biophysics of the Ministry of Education, Cardio-X Institute, College of Life Science and Technology and Center of Human Genome Research, Huazhong University of Science and Technology, Wuhan, China) ,  Mallat Ziad (Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK) ,  Xia Ni (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Xia Ni (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Cheng Xiang (Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Cheng Xiang (Key Laboratory of Biological Targeted Therapy of Education Ministry and Hubei Province, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
資料名： British Journal of Pharmacology  (British Journal of Pharmacology)
巻： 175  号： 8  ページ： 1329-1343  発行年： 2018年 
JST資料番号： B0334A  ISSN： 0007-1188  CODEN： BJPCB  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 背景およびPURPOSE:免疫系は,心筋虚血/再灌流障害(MIRI)後の急性炎症反応の駆動において重要な役割を果たしている。IL-21は複数の免疫調節効果を有する多面的サイトカインであるが,MIRIにおけるその役割は知られていない。実験的APPROACH:心筋障害,好中球浸潤および好中球ケモカインKC(CXCL1)およびMIP-2(CXCL2)の発現を,MIRIのマウスモデルで研究した。新生児マウス心筋細胞(CMs)と心臓線維芽細胞(CFs)におけるKCとMIP-2の発現に及ぼすIL-21の影響をリアルタイムPCRとELISAによって測定した。これらの効果の基礎となるシグナル伝達機構をウェスタンブロット分析により調べた。重要な結果:IL-21は,マウスMIRIの急性期に上昇した。IL-21の中和は,梗塞サイズの減少,心臓トロポニンTレベルの低下,および心機能の改善によって示されるように,心筋障害を減弱させたが,外因性IL-21投与は反対の効果を発揮した。IL-21は好中球の浸潤を増加させ,MIRI後の心筋組織におけるKCとMIP-2の発現を増加させた。さらに,好中球枯渇はIL-21誘導心筋障害を減弱させた。機構的に,IL-21は新生児のCMおよびCFsにおけるKCおよびMIP-2の産生を増加させ,遊走アッセイによって明らかにされたように好中球遊走を増強した。さらに,ケモカイン発現におけるこのIL-21仲介増加は,CFにおけるCMとp38 MAPK/NF-κBシグナル伝達におけるAkt/NF-κBシグナル伝達の活性化を含むことを示した。結論:著者らのデータは,IL-21がMIRIにおいて病原性の役割を果たすという新しい証拠を提供し,心臓の好中球浸潤を促進する可能性がある。したがって,IL-21の標的化はMIRIの治療として治療的可能性を有する可能性がある。Copyright 2018 Wiley Publishing Japan K.K. All Rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： ターゲティング ,  心筋疾患 ,  新生児 ,  ケモカイン ,  治療法 ,  *好中球 ,  リアルタイムPCR法 ,  *心筋 ,  ウェスタンブロット法 ,  病原性 ,  心筋細胞 ,  ELISA
準シソーラス用語： MIP2 ,  *好中球浸潤 ,  *インターロイキン21 , 【Automatic Indexing@JST】

分類 (2件)： 酵素製剤・酵素阻害剤の基礎研究  (GW21010W) ,  呼吸・呼吸器作用薬の基礎研究  (GW08010J)

タイトルに関連する用語 (6件)： IL-21 ,  好中球浸潤 ,  調節 ,  心筋虚血 ,  再潅流障害 ,  促進